Cerebrolysin
Also known as: FPF-1070
Cerebrolysin is not a single peptide but a complex biologic produced by enzymatic hydrolysis of purified porcine brain tissue, containing low-molecular-weight peptides (<10 kDa) and free amino acids. Manufactured by EVER Pharma (Austria), it is registered in 50+ countries (Europe, Asia, Russia, Latin America) for ischemic stroke, traumatic brain injury, and dementia, but is NOT FDA-approved in the United States.
Pricing for Cerebrolysin
Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.
No COAs on file for Cerebrolysin
No third-party tests indexed yet. Phase 2 will surface more vendor evidence as the dataset grows.
28 citations indexed for Cerebrolysin
Study · 2026
Exosomes Released by Cerebrolysin-Treated Cerebral Endothelial Cells Reverse Fibrin- or tPA-Impaired Endothelial Cell Permeability
Cerebrolysin has a salutary effect on impaired cerebral endothelial cell (CEC) permeability. Using an in vitro endothelial permeability assay, the present study tested the hypothesis that exosomes released by Cerebrolysin-treated CECs (Cerebro-Exos) have a robust therapeutic effect on dysfunctional CECs.
Study · 2026
ABSTRACT NUMBER: ESOC2026A2077 NEUROD AND NNT1 AS PREDICTORS OF THE OUTCOMES IN ACUTE ISCHEMIC STROKE PATIENTS UNDERGOING MECHANICAL THROMBECTOMY
Study · 2026
ABSTRACT NUMBER: ESOC2026A562 CEREBROLYSIN AFTER ENDOVASCULAR THROMBECTOMY IN STROKE: 12-MONTH FUNCTIONAL OUTCOMES IN A PROPENSITY-MATCHED COHORT
Study · 2026
ABSTRACT NUMBER: ESOC2026A822 VIRTUAL REALITY NEURORREHABILITATION IN ACUTE STROKE PATIENTS AND THE ADD-ON EFFECT OF CEREBROLYSIN
Study · 2026
ABSTRACT NUMBER: ESOC2026A102 META-ANALYSIS: THE EFFECT OF CEREBROLYSIN COMBINED WITH SPEECH THERAPY ON NONFLUENT APHASIA RECOVERY AFTER ISCHEMIC STROKE
Study · 2026